Sun Pharma

Pharma investors think small as US compliance woes hit heavyweights

Investors in India's $15 billion pharmaceutical industry are favouring smaller firms with little or no exposure to the United States.

Pharma investors think small as US compliance woes hit heavyweights

Brokerages lower Sun Pharmaceutical’s earnings forecast on USFDA caution

Bank of America Merrill Lynch (BofAML), CLSA, Credit Suisse, Equirus Securities and Motilal Oswal Financial Services slashed their earnings estimates in the range of 5-15% for the next two fiscal years.

Maintain neutral on Sun Pharma, target price Rs 817

Sun Pharma on 19 December 2015 announced that the USFDA has issued a warning letter for its Halol formulation facility.

Maintain neutral on Sun Pharma, target price Rs 817

11 top stocks that remained in focus today: Sun Pharma, Indigo, Adani Power and more

Adani Power shares closed 9.25 per cent up at Rs 30.70 after the company announced that it has incorporated a wholly-owned subsidiary firm, Adani Power (Jharkhand) Ltd.

11 top stocks that remained in focus today: Sun Pharma, Indigo, Adani Power and more

Sun Pharma shares gain on divestment of US manufacturing unit

Sun Pharma shares gained after the pharma major informed BSE that one of its wholly-owned subsidiaries has entered into an agreement with Nostrum Laboratories Inc for the divestment of the Bryan (Ohio) unit in the US.

Sun Pharma shares gain on divestment of US manufacturing unit

7 top stocks that remained in focus today: Jain Irrigation, Lux Industries and more

Adani Enterprises shares ended 4.53 per cent up at Rs 78.50 on reports that an Australian court has rejected a bid by environmentalists to stop its $16.5 billion controversy-hit Carmichael coal mine project.

7 top stocks that remained in focus today: Jain Irrigation, Lux Industries and more

Sun Pharma inks pact to develop nervous system drugs

Sun Pharma will have the exclusive option to conduct further development of the enzyme after completion of the pre-clinical studies.

Sun Pharma inks pact to develop nervous system drugs

Sun Pharma surges over 6 per cent on USFDA approval

Sun Pharma shares gained after one of its subsidiaries has received USFDA approval to manufacture and market generic version of Novartis' Gleevec, used in treatment of cancer, in America.

Sun Pharma surges over 6 per cent on USFDA approval

Sun Pharma shares gain over 4% after aborting wind energy investment

Shares of Sun Pharmaceutical Industries gained as much as 4.5 per cent on Thursday after the company on Tuesday announced that its Israeli arm Taro has decided not to proceed with an investment in a wind energy project in the

Sun Pharma shares gain over 4% after aborting wind energy investment

Sun Pharma eyes expansion global consumer healthcare space

Pharmaceutical major Sun Pharma is looking to expand its business in the global consumer healthcare space and is not averse to acquiring new brands, a top company executive said today.

Sun Pharma eyes expansion global consumer healthcare space

Top 3 companies lose Rs 32,447 cr in m cap; Sun Pharma hit hard

Led by Sun Pharma, three of the top 10 most valued Indian companies together saw erosion of Rs 32,447.1 crore from their market capitalisation last week.

Top 3 companies lose Rs 32,447 cr in m cap; Sun Pharma hit hard

Sun Pharma completes acquisition of InSite Vision

Post merger, InSite Vision has become an indirect wholly-owned subsidiary of Sun Pharma.

Sun Pharma completes acquisition of InSite Vision

Sun Pharma acquires US-based InSite Vision

InSite has become an indirect wholly owned subsidiary of Sun Pharma Sun Pharmaceutical Industries has successfully completed the acquisition of InSite Vision. The acquisition was completed by means of a short-form merger unde

Ranbaxy integration: Sun Pharma may drop some non-strategic units

Sun Pharma may discontinue certain non-strategic businesses as part of its integration process with Ranbaxy Laboratories, which it acquired in a USD 4 billion deal last year.

Ranbaxy integration: Sun Pharma may drop some non-strategic units

Sun Pharma recalls over 10 lakh boxes of allergy drug in US

The recall was initiated on July 28 this year Sun Pharma is recalling over ten lakh boxes of its anti-allergic Loratadine drug from the US market as the lot was found to be ‘super potent’ and ‘out of specifi

Advertisement

 

Stock Market

Advertisement
Advertisement

TRENDING NOW

BUDGET 2019

Related Articles

Switch to Hindi Edition
FinancialExpress_1x1_Imp_Desktop